Subscribe To
NUVL / Nuvalent to Present at the 2022 Jefferies Healthcare Conference
NUVL News
By The Motley Fool
October 17, 2023
Why Nuvalent Stock Tanked on Tuesday
The biotech announced a secondary share flotation. It will sell over 5 million shares of its common stock in a public offering. more_horizontal
By The Motley Fool
October 5, 2023
Why Nuvalent Stock Skyrocketed 35% This Week
Nuvalent announced favorable preliminary data from a phase 1 trial indicating its drug NVL-655 was well tolerated with mild adverse events. It's still more_horizontal
By Zacks Investment Research
October 5, 2023
Nuvalent (NUVL) Soars 36% on Upbeat Initial NSCLC Study Data
Nuvalent (NUVL) surges 36% on encouraging preliminary results from the phase I dose-escalation portion of its early-mid-stage development program for more_horizontal
By Seeking Alpha
October 5, 2023
Nuvalent Stock Gains On Lung Cancer Data, But I'd Only Buy On Dip
Nuvalent, Inc. stock gained 36% and reached an all-time high of $58 per share yesterday, with a market cap valuation of $3.3bn. The biotech company is more_horizontal
By The Motley Fool
October 4, 2023
Why Nuvalent Stock Was Soaring Wednesday
Nuvalent is a clinical-stage biotech. The company said its therapy showed effectiveness and a strong safety profile in its phase 1/2 trial to treat AL more_horizontal
By Zacks Investment Research
July 21, 2023
Recent Price Trend in Nuvalent, Inc. (NUVL) is Your Friend, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Nuvalent, Inc. (NUVL) could be a great choice. It is one of t more_horizontal
By Zacks Investment Research
June 7, 2023
Nuvalent, Inc. (NUVL) Is a Great Choice for 'Trend' Investors, Here's Why
Nuvalent, Inc. (NUVL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks more_horizontal
By PRNewsWire
March 23, 2023
Nuvalent to Present ALKOVE-1 Trial in Progress Poster for NVL-655 at the European Lung Cancer Congress (ELCC 2023)
CAMBRIDGE, Mass. , March 23, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating preci more_horizontal